Granted Patent B2

US 12,312,340 · App. 18/590,713 · Granted May 27, 2025

Inventors: Jason Allan Wiles (Madison, CT); Srinivasa Karra (Pembrooke, MA); Mark George Saulnier (Higganum, CT); Jesse Jingyang Chen (Lexington, MA); Kevin Tyler Sprott (Needham, MA); Soumya Ray (Quincy, MA)

Assignee: Avilar Therapeutics, Inc.

C07D405/12C07D405/14C07D417/12C07H5/06C07H17/02

Abstract

Claims (35)

1. A compound selected from:

or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1 , wherein the compound is of structure:

or a pharmaceutically acceptable salt thereof.

3. The compound of claim 1 , wherein the compound is of structure:

or a pharmaceutically acceptable salt thereof.

4. The compound of claim 1 , wherein the compound is of structure:

or a pharmaceutically acceptable salt thereof.

5. The compound of claim 1 , wherein the compound is of structure:

or a pharmaceutically acceptable salt thereof.

6. A compound selected from:

or a salt thereof.

7. The compound of claim 6 , wherein the compound is of structure:

or a salt thereof.

8. The compound of claim 6 , wherein the compound is of structure:

or a salt thereof.

9. The compound of claim 6 , wherein the compound is of structure:

or a salt thereof.

10. The compound of claim 6 , wherein the compound is of structure:

or a salt thereof.

11. A compound of the formula

or a pharmaceutically acceptable salt thereof,

wherein:

ASGPR Binding Ligand is

R 1 is a bond to Linker A ;

R 66 and R 67 are hydrogen;

R 5 is C 0 -C 6 alkyl-OR 6 ;

C 0 -C 6 alkyl is —CH 2 —;

R 6 is hydrogen;

Linker A is

R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 , and R 20 are independently at each occurrence selected from the group consisting of a bond, alkyl, —O—, —S—, —NR 6 —, —CH 2 CH 2 —[O—(CH 2 ) 2 ] n —O—, —CH 2 CH 2 —[O—(CH 2 ) 2 ] n —NR 6 —, —CH 2 CH 2 —[O—(CH 2 ) 2] n —, —[—(CH 2 ) 2 —O—] n —, and —[O—(CH 2 ) 2 ] n —;

n is independently selected at each instance from 1, 2, 3, 4, 5, 6, 7, or 8;

Linker C is

and

Immunoglobulin Targeting Ligand is selected from

Assignments (2)

Continuity (7)

References Cited (150)